About this course
This course gives you an overview of the drug discovery and development processes where disease-targeted research leads to clinical treatments. Recent advances within medical biotechnologies and the latest treatment approaches are introduced, including stem cell technology, immunotherapies, and modern vaccine development, such as those created to combat SARS-CoV-2, the virus causing COVID-19.
You will visit European pharmaceutical and biotechnology communities, university/hospital labs and start-up companies and get an insight into the business aspects of drug development and the many job niches of the field.
Syllabus
Syllabus Section B – Fall 2024
Go to syllabusSyllabus Section C – Fall 2024
Go to syllabusPre-requisites
One year each of biology and chemistry at university level.
Faculty
Jeanette Erbo Wern
Faculty; Senior Research ManagerPostdoc (Inst. of International Health, Immunology and Microbiology, University of Copenhagen, Denmark, 2006-2009). Ph.D. (Immunology, Inst. Of International Health, Immunology and Microbiology, University of Copenhagen, 2005). M.Sc. (Inst. Of International Health, Immunology and Microbiology, University of Copenhagen, 2001). Senior Scientist, Immune Targeting Group, Bioneer, Copenhagen, Denmark, 2010-2013. Senior Scientist, Dept. of Infectious Disease Immunology, Statens Serum Institute, Copenhagen, Denmark, 2013-2016. With DIS since 2016.
Samra Sardar
FacultyBachelor of Medicine, Bachelor of Surgery (M.B.B.S.), University of Health Sciences Pakistan, 2003-2009. M.Sc., Molecular Biology, Vrije University Brussels, 2010-2011. Ph.D., Immunology & Infectious Diseases, University of Copenhagen, 2013-2017. Research Scientist, Nordic Bioscience, 2018-2019. Global Medical Manager, Leo Pharm, 2019-2022. Global Medical Lead Grunenthal, 2022-2024. Managing Director, PharmaTech Consult, 2024-Present. With DIS since 2024.
Reza Yarani
FacultyPh.D (Cellular and Genetic Medicine, Department of Cellular and Molecular Biology, University of Copenhagen, 2016). Assistant Professor, Translational Type 1 Diabetes Research, Department of Clinical Research, Steno Diabetes Center Copenhagen, 2021-Present. With DIS since 2023.